MDM2 Copy Numbers in Well Differentiated and Dedifferentiated Liposarcoma: Where Do We Draw the Line?

被引：0
|
作者：
Ware, P. [1 ]
Snow, A. [1 ]
Pettenati, M. [1 ]
Qasem, S. [1 ]
机构：
[1] Wake Forest Univ, Baptist Med Ctr, Winston Salem, NC 27109 USA
来源：
MODERN PATHOLOGY | 2012年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
82
引用
收藏
页码：22A / 22A
页数：1
相关论文
共 50 条
  • [21] PREVENTION - WHERE DO WE DRAW THE LINE
    BROWN, RB
    DAFCIK, A
    FRIEDLAND, M
    ANNALS OF INTERNAL MEDICINE, 1991, 114 (08) : 706 - 707
  • [22] Milademetan, an oral MDM2 inhibitor, in well-differentiated/dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas
    Gounder, M. M.
    Bauer, T. M.
    Schwartz, G. K.
    LoRusso, P.
    Kumar, P.
    Kato, K.
    Tao, B.
    Hong, Y.
    Patel, P.
    Hong, D.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S3 - S4
  • [23] MDM2-p53 Pathway Status in Clinical Samples of Well-Differentiated and Dedifferentiated Liposarcoma
    Kumagai, A.
    Motoi, T.
    Yoshida, A.
    Imamura, T.
    Fukusato, T.
    LABORATORY INVESTIGATION, 2011, 91 : 17A - 17A
  • [24] Does MDM2 Amplification Ratio Relate with Dedifferentiation and Predict Prognosis in Well differentiated/Dedifferentiated Liposarcomas?
    Gomez, Ariannette Robledo
    Chopra, Shefali
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 61 - 62
  • [25] DEGREE OF MDM2 AMPLIFICATION AFFECTS CLINICAL OUTCOMES IN DEDIFFERENTIATED LIPOSARCOMA.
    Seligson, N. D.
    Bill, K. L. J.
    Hays, J. L.
    Demoret, B.
    Stets, C. W.
    Duggan, M.
    Bupathi, M.
    Shakya, R.
    Timmers, C.
    Walely, P. E.
    Pollock, R. E.
    Chen, J. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S38 - S38
  • [26] Does MDM2 Amplification Ratio Relate with Dedifferentiation and Predict Prognosis in Well differentiated/Dedifferentiated Liposarcomas?
    Gomez, Ariannette Robledo
    Chopra, Shefali
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 61 - 62
  • [27] Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting
    Dadone-Montaudie, Berengere
    Laroche-Clary, Audrey
    Mongis, Aline
    Chamorey, Emmanuel
    Di Mauro, Ilaria
    Chaire, Vanessa
    Finetti, Pascal
    Schiappa, Renaud
    Le Loarer, Francois
    Birtwisle-Peyrottes, Isabelle
    Michiels, Jean-Francois
    Bertucci, Francois
    Pedeutour, Florence
    Italiano, Antoine
    Bianchini, Laurence
    CANCERS, 2020, 12 (10) : 1 - 20
  • [28] Metastatic Uterine Leiomyosarcoma With MDM2 Amplification Mimicking Dedifferentiated Liposarcoma: A Diagnostic Pitfall
    Agaimy, Abbas
    Frohnauer, Judith
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2015, 34 (02) : 177 - 179
  • [29] MDM2-p53 Pathway Status in Clinical Samples of Well-Differentiated and Dedifferentiated Liposarcoma.
    Kumagai, A.
    Motoi, T.
    Yoshida, A.
    Imamura, T.
    Fukusato, T.
    MODERN PATHOLOGY, 2011, 24 : 17A - 17A
  • [30] Dedifferentiated Liposarcoma and Pleomorphic Liposarcoma: A Comparative Study on FNA Cytomorphology and MDM2/CDK4 Expression
    Marino-Enriquez, A.
    Hornick, J. L.
    Cibas, E. S.
    Qian, X.
    MODERN PATHOLOGY, 2013, 26 : 97A - 97A
12345